Indolent primary cutaneous T-cell lymphoma

Indolent primary cutaneous T-cell lymphoma (CTCL) refers to a group of non-Hodgkin lymphomas that originate in the skin from mature T-lymphocytes and follow a slow, favorable clinical course. This category encompasses several subtypes, including mycosis fungoides (the most common form), primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, subcutaneous panniculitis-like T-cell lymphoma, and primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. These indolent forms are distinguished from aggressive primary cutaneous T-cell lymphomas by their generally good prognosis and prolonged survival. The disease primarily affects the skin, presenting with patches, plaques, papules, nodules, or tumors depending on the specific subtype and stage. Patients may experience persistent, slowly evolving skin lesions that can be flat and scaly (as in early mycosis fungoides) or raised nodular lesions (as in primary cutaneous anaplastic large cell lymphoma). Itching (pruritus) is a common and sometimes debilitating symptom. In most indolent forms, the disease remains confined to the skin for prolonged periods, though periodic monitoring is essential as progression can occasionally occur. Treatment is typically directed at the skin and depends on the subtype and extent of disease. Skin-directed therapies include topical corticosteroids, phototherapy (PUVA or narrowband UVB), topical chemotherapy agents such as mechlorethamine or carmustine, and localized radiation therapy. For more widespread or refractory disease, systemic options may include retinoids (bexarotene), interferon-alpha, low-dose methotrexate, or targeted therapies. Given the indolent nature, a watch-and-wait approach may be appropriate for some subtypes such as lymphomatoid papulosis. The overall prognosis for indolent primary cutaneous T-cell lymphomas is generally favorable, with many patients having a normal or near-normal life expectancy.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Indolent primary cutaneous T-cell lymphoma